anlotinib and sintilimab
Phase 2Monoclonal antibody
anlotinib and sintilimab is one of 84 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
193 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Avastin
RochePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Cyramza
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer1 trial
Gastric Cancer1 trial
Hepatocellular Carcinoma1 trial
Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04052152·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anlotinib and sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Changzheng Hospital